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Abstract
Background: P24 protein is the major core protein of HIV virus particle and has been suggested as a specific
target for antiviral strategies. Recombinant p24 protein with natural antigenic activity would be useful for various
studies, such as diagnostic reagents and multi-component HIV vaccine development. The aim of this study was to
express and purify the p24 protein in soluble form in E.coli.
Results: According to the sequence of the p24 gene, a pair of primers was designed, and the target sequence of
700 bp was amplified using PCR. The PCR product was cloned into pQE30 vector, generating the recombinant
plasmid pQE30-p24. SDS-PAGE analysis showed that the His-tagged recombinant p24 protein was highly expressed
in soluble form after induction in E. coli strain BL21. The recombinant protein was purified by nickel affinity
chromatography and used to react with HIV infected sera. The results showed that the recombinant p24 protein
could specifically react with the HIV infected sera. To study the immunogenicity of this soluble recombinant p24
protein, it was used to immunize mice for the preparation of polyclonal antibody. Subsequent ELISA and Western-
Blot analysis demonstrated that the p24 protein had proper immunogenicity in inducing mice to produce HIV p24
specific antibodies.
Conclusion: In this work, we report the high level soluble expression of HIV-1 p24 protein in E. coli. This soluble
recombinant p24 protein specifically react with HIV infected sera and elicit HIV p24 specific antibodies in mice,
indicating this soluble recombinant p24 protein could be a promising reagent for HIV diagnosis.
Background
The human immunodeficiency virus type 1 (HIV-1) is
the main cause of the acquired immunodeficiency syn-
drome (AIDS)[1]. Diagnosis of HIV infection, especially
early diagnosis, is one of important part of AIDS pre-
vention and control[2]. Gag protein of HIV-1, a poly-
protein of 55 kDa, is one of the most conserved viral
proteins. The Gag protein is cleaved by a viral protease
to release p17, p24 and p12 during viral maturation[3].
P24 protein is the major core protein of the virus parti-
cle and has been suggested as a specific target for
antiviral strategies[4]. P24 protein is one of the detecting
targets of most diagnostic kits. P24 antigen detection is
also helpful for early diagnosis of HIV-infection[5]. The
fourth-generation test assays for HIV infection is estab-
lished on the basis of the p24 antigen detection and is
able to find the HIV-infected at an early stage, resulting
in shortened diagnostic windows[6]. The p24 protein
also can be used as an integral part of any multi-compo-
nent HIV vaccine[7,8].
A proper recombinant p24 protein with the same anti-
gentic activity as natural p24 protein would be useful for
a number of studies. The p24 protein have been pro-
duced in a wide variety of systems, including Escherichia
coli[9], Pichia pastoris[10], plant-based expression sys-
tem[11,12], baculovirus-insect cell[3], etc. In this study,
a recombinant plasmid was constructed to express the
His-tagged p24 protein in Escherichia coli.T h ep r o t e i n
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2
+-NTA affinity chromatography. Enzyme-linked immu-
nosorbant assay (ELISA) and Western blot analysis
demonstrated that the recombinant p24 proteins exhib-
ited good immunoreactivity and immunogenicity.
Methods
Strains, plasmids, enzymes and reagents
The E. coli strains DH5a and BL21(DE3) were used for
cloning experiments and protein expressions, respec-
tively. Both strains were purchased from Invitrogen
(Novagen, Shanghai, China). Plasmid pQE30 (Novagen,
Darmstadt, Germany) was used for recombinant protein
expression. Restriction enzymes, Taq DNA polymerase,
and T4 ligase were purchased from TaKaRa Biotechnol-
ogy Co. (Dalian, China).
Construction of the plasmid expressing the p24 protein
The HIV-1 p24 open reading frame was amplified from
plasmid pHIV which contains the HIV-1 NY5 and LAV
strain hybrid genome [13] with the forward primer (5’-
GAG GAT CCC CCA TAG TGC AGA ACC TC-3’,
BamHI site underlined), and the reverse primer (CCG
GTA CCT TAG AAA ACT CTT GCT TTA TG-3’,
KpnI site underlined). The PCR product was digested
with BamHIa n dKpnI and inserted into the prokaryotic
expression pQE30 digested with the same enzymes to
create the p24 expression plasmid pQE30-p24.
Expression of the p24 protein
E.coli BL21 transformed with pQE30-p24 was cultured
in LB medium supplemented with 50 μg/ml ampicillin
for growth at 37°C until the logarithmic phase (at
O D 6 0 0o f0 . 5 - 0 . 6 )a n di n d u c e db yi s o p r o p y l - b-D-Thio-
galactoside (IPTG) at a final concentration of 1.0 mM
for 12 h at 20°C. The bacterial lysates were subjected to
15% SDS-PAGE, and Bandscan5.0 software was applied
to assess the expression of the fusion protein.
Characterization of the solubility of the p24 protein
To assess the solubility of the His-tagged p24 protein,
logarithmic phase bacterial cultures were pelleted and
suspended in 20 mM Tris-HCl lysis buffer (pH 8.0) sup-
plemented with 100 mM NaCl, 1.0 mM phenylmethyl
sulfonylfluoride (PMSF), 50 mg/ml lysozyme and sub-
jected to sonication on ice until clear. The total bacterial
proteins were then partitioned into soluble and insoluble
fractions by centrifugation at 14,000 × g for 20 min at 4°
C. The supernatant (soluble fraction) was collected and
the pellets (insoluble fraction), which contained the
inclusion bodies, were suspended in deionized water.
Both fractions were analyzed in parallel by 15% SDS-
PAGE to characterize the solubility of the His-tagged
p24 protein.
Purification of the p24 protein
The supernatant was filtered through a 0.45-μmm e m -
brane (Pall Corporation, USA) and then loaded onto a
gravity-flow column packed with 2 ml Ni
2+-NTA resin
slurry (Qiagen, Germany). His-tagged p24 fusion pro-
teins were purified following the manufacturer’sh a n d -
book for high-level expression and purification of
6×His-tagged protein and the yield was quantified using
a Coomassie Protein Assay Kit (Biomed, China). 15%
SDS-PAGE was performed to validate the identity and
evaluate the purity of the target fusion protein.
Recombinant p24 protein identification
To confirm the presence and the apparent molecular
mass of the recombinant proteins expressed in E. coli,
Western blot was carried out using anti-His antibody
(Sigma). The purified recombinant p24 protein were
separated by 15% SDS-PAGE, electrotransferred onto a
nitrocellulose membrane (GE Healthcare, USA) and
blocked with 5% non-fat dry milk in TBS (50 mM Tris-
HCl, 150 mM NaCl, pH 7.5) at 37°C for 2 h. After
washing 3 times (each 5 min) with TBS containing
0.05% Tween-20 (TBST), the membrane was incubated
with horseradish peroxidase-conjugated anti-His mono-
clonal antibody. Immunoreactive proteins were then
visualized using the ECL Western blotting analysis sys-
tem (Pierce, Rockford, USA).
Immunoreactivity analysis of the recombinant p24
protein
Human serum samples (n = 90) were obtained from
PLA Center for HIV Test, including forty HIV-1 positive
samples and fifty HIV-1 negative human serum samples.
The protein p24 (1.5 ug/ml in 200 nmol/L NaHCO3
pH9.8, 100 ul/well) were coated on ELISA plates (Nunc,
Roskilde, Denmark) at 4°C overnight. Plates were then
blocked at 37°C for 3 h with 5% non-fat milk and
washed four times with PBST. Human sera were added
as the primary antibody (1:50 dilution) at 37°C for 1 h.
Plates were then washed four times with PBST and
incubated with HRP-conjugated goat anti-human IgG
(1:3000 dilution) at 37°C for 1 h. Color was developed
using TMB solution (Sigma) and absorbance was exam-
ined using an ELISA reader at 450 nm.
Vaccination and HIV-1 p24 specific antibodies detection
Three females BALB/c mice, 8-week-old (purchased
from the Center of Experimental Animals, Academy of
Military Medical Sciences, Beijing) were injected intra-
dermally on the back and abdomen with 80 μgp u r i f i e d
His-tagged p24 protein mixed with complete Freund’s
adjuvant (100 μl per site). Pre-immune mouse sera were
collected prior to immunization. After three immuniza-
tions within an interval of 21 days, these immunized
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stood at 4°C for 2 h, and the sera were aspirated after
centrifugation at 4000 rpm for 10 min at 4°C. Serum
samples were serially diluted from 1:500, to 1:8192000
and anti-p24 antibodies titer were determined by indir-
ect ELISA with recombinant p24 protein. Western blot-
ting was performed with cultured HIV-1 extracts to
detect the antibodies specificity.
Results
Construction of p24 prokaryotic expression plasmid
The p24 gene was amplified from plasmid pHIV (Figure
1). The PCR product was digested with BamHIa n d
KpnI and inserted into pQE30 digested with the same
enzymes to yield the recombinant plasmid pQE30-p24.
The pQE30-p24 construct was verified by restriction
enzyme digestion and DNA sequencing (data not
shown).
Expression, purification and identification of the
recombinant p24 proteins
E.coli BL21 transformed with pQE30-p24 was cultured in
LB medium supplemented with 50 μg/ml ampicillin for
growth at 37°C until the logarithmic phase (at OD600 of
0.5-0.6) and induced by isopropyl-b-D-Thiogalactoside
(IPTG) at a final concentration of 1.0 mM for 12 h at 20°
C (In preliminary experiments, the optimal temperature
for obtaining high level expression of p24 was deter-
mined to be 20°C). A distinct band of approximately 24
kDa, corresponding to the expected molecular weight of
the His-tagged p24 protein, was found only after induc-
tion, whereas there was no expression of the p24 protein
either in BL21 harboring pQE30-p24 without IPTG
induction, BL21 alone or BL21 with pQE30 (Figure 2).
Densitometry scan after SDS-PAGE analysis exhibited a
relatively high expression level of the recombinant pro-
tein, which constituted approximately 20.4% of the total
proteins. According to the SDS-PAGE analysis of the
soluble fraction and cell debris pellet, the majority of the
induced protein was found in the soluble fraction, sug-
gesting that the His-tagged p24 protein was mainly in
soluble form (Figure 3).
Purification of the His-tagged p24 protein was per-
formed with a Ni2+-NTA resin column. The SDS-PAGE
analysis of the elution showed a single target band cor-
responding to the expected molecular weight of p24-
HIS (24 kDa) (Figure 3). To confirm the presence of the
p24-HIS protein, Western blot was carried out using
anti-His antibody. Specific blotting bands were detected
at the corresponding positions (Figure 4).
Figure 1 PCR amplification of HIV p24 gene. Lane 1, the
amplified product of HIV p24 (about 700 bp); Lane 2, DNA marker
2000 (TaKaRa, Dalian, China);
Figure 2 The SDS-PAGE analysis of recombinant p24 protein.
Lane M, Protein molecular marker; Lane 1, E.coli BL21(DE3) whole
cell harboring pQE30-p24 after induction with IPTG (about 24 kDa);
Lane 2, E. coli BL21(DE3) whole cell harboring pQE30-p24 before
induction with IPTG; Lane 3, host cell E. coli BL21(DE3) (as negative
control); Lane 4, E.coli whole cell harboring empty plasmid pQE30
after induction with IPTG.
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In order to evaluate the potential of the recombinant p24
protein as a diagnostic reagent, it was coated on micro-
plates. Indirect ELISA demonstrated that the recombinant
p24 protein specifically reacted with HIV-infected human
serum samples (positive for all the forty HIV-1 infected
human serum samples tested), and did not with most of
the normal human sera (for the total 50 uninfected sera
tested, only two samples displayed weak positivity, which
may due to the cross reactivity of residual bacterial com-
ponents) (Table 1). These results suggest this recombinant
protein possess proper immunoreactivity.
The immunogenicity of p24 protein expressed in E.coli
Indirect ELISA and Western blot were performed to
access the immunogenicity of the recombinant protein.
After the mice received three times of immunization at 21
days intervals, these immunized mice were sacrificed and
the sera were isolated. For the indirect ELISA, serum sam-
ples were diluted at 1/500, 1/2000, 1/8000, 1:32000,
1:128000, 1:512000, 1:2048000, 1:8192000, respectively,
and were used to react with the recombinant p24 proteins,
with pre-immune serum served as the negative control.
The titer of immunized mice serum was determined to be
more than 1:128000 by indirect ELISA (Figure 5).
In the Western blot analysis of cultured HIV-1
extract, the sera from immunized mice were used as the
capture antibody and HRP-labeled goat anti-mouse
immunoglobulin G were used as the secondary antibody.
Recombinant p24 protein was used as the positive con-
trol and bovine serum albumin (BSA) as negative con-
trol. Western blotting results showed that the
immunized mouse serum could react with cultured
HIV-1 extract and recombinant p24 protein (Figure 6),
while it could not react with BSA (Figure 6). These
results indicated that p24 protein expressed in E.coli
had proper immunogenicity and could induce mice to
produce specific antibodies against HIV-1.
Discussion
The bacterial expression system is the most universally
used, as it is relatively inexpensive, and with ease of
Figure 3 The SDS-PAGE analysis of the solubility of the
recombinant p24 protein. Lane M, Protein molecular marker; Lane
1, cell extract of E. coli harboring pQE30-p24 (pellets); Lane 2, cell
extract of E. coli harboring pQE30-p24 (supernatant); Lane 3, the
recombinant p24 protein purified by the Ni
2+-NTA agarose gel.
Figure 4 Western blotting analysis of the recombinant p24
protein. Lane 1: E. coli whole cell harboring empty plasmid pQE30
after induction with IPTG; Lane 2: E. coli whole cell harboring
pQE30-p24 after induction with IPTG; Lane 3: cell extract of E. coli
harboring pQE30-p24 after induction with IPTG (pellets); Lane 4: cell
extract of E. coli harboring pQE30-p24 after induction with IPTG
(supernatant); Lane 5: purified His-tagged p24 protein.
Table 1 Efficacy of the recombinant p24 for detecting
antibodies in HIV-infected individuals.
HIV infection p24 ELISA result Total
+ -
Positive sera 40 0 40
Negative sera 2 48 50
Total 42 48
P < 0.001 (c
2 test)
Microtitration plate wells were coated with 150 ng recombinant p24 per well.
Sera were used at 1:50 dilution. HRP-conjugated goat anti-human IgG was
used at 1:3000 dilution.
Figure 5 Titer of anti-p24 antibodies in the immunized mouse
sera determined by indirect ELISA. The prei-mmune serum
served as the negative control. Serum samples were diluted at 1/
500, 1/2000, 1/8000, 1:32000, 1:128000, 1:512000, 1:2048000,
1:8192000.
Zhang et al. Virology Journal 2011, 8:316
http://www.virologyj.com/content/8/1/316
Page 4 of 6manipulation and a rapid growth rate[14]. Problemati-
cally, with the bacterial expression system, inclusion
bodies are often produced due to incorrect folding
and thus require denaturation and renaturation before
further use. These processes may complicate or inhibit
recombinant protein production. Use of a low culture
temperature, low inducer concentrations and the co-
expression of molecular chaperones can promote the
soluble expression of recombinant proteins [15]. In
this study, the soluble p24 protein was highly
expressed at a low temperature (20°C) and a low IPTG
concentration (0.6 mM). To further increase the
recombinant protein solubility, we chose E. coli BL21
(DE3) as the host strain, which was previously demon-
strated to be appropriate for soluble expression[15].
By adopting these strategies, the recombinant p24 pro-
tein was expressed in soluble form and was easily
purified.
It is reported that protein primary structure may influ-
ence soluble protein expression. Change of the amino
acids in proteins (especially cysteine) may significantly
influence the folding and alter the conformation of the
protein. Studies conducted by Strandberg[16] and Wet-
zel et al[17] have shown that a few amino acid changes
can remarkably alter the soluble expression of target
protein, and Rinas et al[18] have also reported that indi-
vidual amino acid changes involving cysteine drastically
changed the solubility of recombinant proteins.
Up to now, there are a few reports about of HIV p24
protein expression[10,12,19,20]. Some studies have used
complicated strategies to achieve soluble p24 expression
[7,21,22]. For our knowledge, up to now, no one has
reported a simple method for soluble p24 protein
expression. Like this report, Gupta et al[9] used the
pQE30 to express recombinant p24 protein, but the
recombinant p24 protein was produced as inclusion
bodies. Our soluble p24 protein differed from Gupta’s
insoluble p24 protein in a few amino acids, including
cysteine residues. The solubility of our p24 protein may
be attributed to Cys230 which located in the C-terminal
(Figure 7). The Cys230 and Cys210 are likely to form an
intra-chain disulfide bonds, resulting in a small ring.
This structure may promote the proper fold of the
recombinant protein.
The early diagnosis of HIV infection is very important
for prevention of HIV spread and ensuring safety of
blood products[19]. Currently most diagnostic reagents
are based on the method of ELISA for detection of anti-
bodies against HIV proteins[19,23]. Synthetic peptides
and/or recombinant proteins spanning the envelope
(gp41 of HIV-1 and gp36 of HIV-2 respectively) and the
core (p24) proteins are often used as capture antigens
[19]. Antibodies directed against p24 appear early in
HIV infection and are reported to decline with progres-
sion of the disease due to increasing antigenemia[24]. It
is reported that synthetic peptides (9-53-mer) corre-
sponding to p24 did not give satisfactory results[9].
Recombinant p24 protein may be a better option com-
pared with synthetic peptides. In this paper, we report
the high level soluble expression of HIV-1 p24 protein
in E. coli. This soluble recombinant p24 protein specifi-
cally reacts with HIV-1 infected sera. To study the
immunogenicity of this soluble recombinant p24 pro-
tein, it was used to immunize mice for preparation of
polyclonal antibody. Subsequent ELISA and Western-
Blot analysis demonstrated that the p24 protein had
proper immunogenicity in inducing mice to produce
HIV-1 p24 specific antibodies. Recently the fourth gen-
eration HIV assays include the p24 antigen detection,
thus high affinity antibodies with high specificity for p24
is a pre-requisite. A good recombinant protein may be a
great help to manufacturing qualified p24 antibodies.
Our soluble p24 protein which has exhibited good
immunoreactivity and proper immunogenicity may help
Figure 6 Antibody specificity of mouse sera immunized with
the recombinant p24 protein. Lane 1: recombinant p24 protein.
Lane 2: cultured HIV-1 extract. Lane 3: BSA (negative control). Arrow
at the left indicates the position of p24 protein.
Figure 7 Sequence comparison between soluble and insoluble
p24 protein synthesized in E. coli. A. Sequence of the soluble
p24 protein in this report; B. Sequence of the insoluble p24 protein
reported by Gupta. * indicates the amino acid difference. # indicates
the Cys residue. The artificial regions are underlined.
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further research.
Conclusions
In this study, we have highly expressed soluble recombi-
nant HIV-1 p24 protein in E.coli. This soluble p24 had
good immunoreactivity and immunogenicity. Its charac-
teristics suggest that this recombinant p24 protein holds
promise for assembling the HIV diagnostic kits, as well
as for the development of the fourth generation HIV
test kits.
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